Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Nonsteroidal anti-inflammatory drugs and hormonal therapy
12 evidence topics · 12 sources
Desmoid Tumor Working Group position on antihormonal therapies and NSAIDs
Hormone antagonists no longer recommended by the Desmoid Tumor Working Group
“Note that nirogacestat was not approved for use at the time of survey completion [18], and hormone antagonists are no longer recommended by Desmoid Tumor Working Group Consenus Guidelines [13]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of NSAIDs and hormone antagonists reported in this study is only recommended for certain circumstances by evidence-based guidelines [14, 16].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NCCN placement of NSAIDs for pain as quoted in a payer policy
“Sulindac or other nonsteroidal” (opens the source at this quote in a new tab)
“including celecoxib, are recommended for pain under” (opens the source at this quote in a new tab)
“Useful in Certain Circumstances” (opens the source at this quote in a new tab)
“(category 2A).” (opens the source at this quote in a new tab)
European consensus position on antihormonal therapy, 2017, superseded in 2020
“Anti-hormonal agents such as tamoxifen may be used—alone [60] or in combination with NSAIDs [61]—as first medical treatment, mainly because of their limited toxicity, rare adverse events and low costs [62] (III, B). However, response rates have been found to be low and no clear relationship between symptom changes, size or MRI signal changes could be demonstrated [63]. Therefore, a general recommendation for its use cannot be given.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
High-dose tamoxifen plus sulindac in a German institutional series
“Since 1992, 25 patients at Heinrich Heine University (Dusseldorf, Germany) were treated with a combination of tamoxifen and sulindac.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the current study, 17 patients with FAP-associated and 8 patients with sporadic desmoid tumors received 120 mg of tamoxifen and 300 mg of sulindac daily.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the group of patients who received tamoxifen and sulindac as a primary treatment, all three patients with sporadic desmoid tumors demonstrated cessation of growth, and 10 of the 13 patients with FAP-associated tumors achieved either a PR or CR.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Based on this experience, the authors recommended high-dose tamoxifen and sulindac as the primary treatment for patients with FAP-associated desmoid tumors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
High-dose selective estrogen receptor modulators plus sulindac in an institutional cohort
“This study included all desmoid patients that were treated and followed at our institution and had completed at least 1 year of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 134 patients were included. 64 (47.8 %) patients had a confirmed diagnosis of FAP, 69 (51.5 %) patients were sporadic. Overall 114 (85.1 %) patients showed regressive or stable desmoid size.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Response was defined as stable size or regression of desmoid size between two CT or MRI scans.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tamoxifen plus sulindac in children in a Children's Oncology Group phase 2 study
“We evaluated the safety and efficacy of tamoxifen and sulindac in a prospective phase II study within the Children’s Oncology Group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No life-threatening toxicity was reported. Twelve (40%) of 30 females developed ovarian cysts, which were asymptomatic in 11 cases. Ten patients completed therapy without disease progression or discontinuing treatment. Responses included four partial and one complete (5/59, 8%). The estimated 2-year PFS and survival rates were 36% (95% confidence interval: 0.23–0.48) and 96%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the combination showed relatively little activity as measured by response and PFS rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Toremifene in a retrospective reference-institution series
“We retrospectively reviewed all patients treated with toremifene between 2005 and 2012 at a reference institution.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-four patients were treated with toremifene 180 mg daily, 20 for radiological progression, 16 for pain and 8 for both.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PFS was 89.6% at 2 years. According to Response Evaluation Criteria in Solid Tumours, partial response, stable disease and disease progression were observed in 25%, 65% and 10% of the patients, respectively. Symptomatic relief was obtained in 75% of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events G≥2 according to National Cancer Institute Common Toxicity Criteria were recorded in ten patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Toremifene at two dose levels in a prospective phase 2 study
“In order to test the dose efficacy and assess activity and safety of toremifene in DF, we conducted this prospective phase 2 study (NCT02353429).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 6 and 12 months progression-free survival (PFS) probability was 14.4% (95% CI, 5.1-41.1) and 4.8% (95% CI, 0.7-32.6) for patients receiving 60 mg compared with 72.0% (95% CI, 54.2-96.2) and 52.5% (95% CI, 33.1-83.3) for those receiving 180 mg.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No toremifene-related serious adverse events were observed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Toremifene at 60 mg daily is ineffective in this patient population. However, clinical benefit was observed at 180 mg in selected cases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of anti-oestrogen therapy
“Data on 168 DTs treated with anti-oestrogen agents, alone or in combination with nonsteroidal anti-inflammatory drugs, were identified with an overall response rate of 51%. There was no difference in response according to the type of DTs or between different anti-oestrogen therapies. Combination with anti-inflammatory drugs did not improve the outcome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Despite potential inaccuracies in the methodology, the results of the review indicate that anti-oestrogen therapy produces some effect in about one half of patients with DTs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Meloxicam response and CTNNB1 mutation status
“Of the 33 patients with meloxicam treatment, one showed complete remission (CR), 7 partial remission (PR), 12 stable disease (SD), and 13 progressive disease (PD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“S45F mutation was significantly associated with a poor response (all cases; PD) (p = 0.017), whereas the other mutations had no impact on efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote